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studied only with great difficulty or at great expense. An
example is the study of vaccination in patients with end-
stage renal disease by Gilbertson et al [7]. By its nature,
such a study could never be attempted in a randomized
trial.
We appreciate this opportunity to discuss our work.
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Challenges from bias when
estimating change of renal
allograft function
To the Editor: In the February issue of Kidney In-
ternational, Gill et al [1] aimed to examine the asso-
ciations between immunosuppressive regimens and the
change of renal allograft function. Their analytical strat-
egy, in concert with missing data and measurement er-
ror that is systematically different between centers that
differentially use types of calcineurin inhibitors, rein-
forces the substantive limitations of using databases to
address particular hypotheses. First, repeated measures
of renal function entail an analytical strategy that con-
siders within subject correlation [2, 3]. Second, change
of renal function may not be measured uniformly during
post-transplant between regimens as a consequence of
the pattern of missingness of serum creatinines across
eras of transplantation, which are associated with the
prevalence of regimens. The time post-transplant when
change is measured is important as the slope of creati-
nine evolves. Third, there is significant calibration bias for
measurement of serum creatinines that exists across med-
ical centers, which is associated with the type of regimen
[4]. The summation of the biases—the lack of consider-
ation for intrasubject correlation, the nonuniform mea-
surement of change of renal function across regimens,
and the measurement error of serum creatinines across
centers, overshadows the meaningfulness of the conclu-
sions, and contributes to the unique observations asso-
ciated with tacrolimus—lowest mean glomerular filtra-
tion rate (GFR) at one year after transplant (see Table 1)
and the implausible positive change of renal function (see
Table 3). Understanding the impact of immunosuppres-
sive strategies on the change of renal function overtime is
important; however, this is best examined in prospective
studies, and caution is advised when applying this study’s
observations to the management of transplant recipients.
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Reply from the Authors
We thank Dr. Mange for his letter drawing attention
to the potential of bias in observational studies such as
ours. He has raised three issues:
First, we agree that longitudinal studies that analyze se-
rial measurements from the same patient must consider
the impact of autocorrelation caused by repeated mea-
sures. We used a two-step regression procedure, which
fully accounts for any effects of repeated measures. Our
primary outcome, the annualized change in GFR, was cal-
culated by fitting a regression line through each patient’s
serial GFR estimates. This accepted technique reduces
the rate of change in GFR to a single outcome measure
per patient—a slope. These slopes were then examined
